Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
Authors:
Open Access
- 15 October 2018
- journal article
- research article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 50 (4) , 1418-1432
Abstract
Alteration of biomarker status after primary systemic therapy (PST) is occasionally found in breast cancer. This study was conducted to clarify the clinical implications of change of biomarker status in breast cancer patients treated with PST. The pre-chemotherapeutic biopsy and post-chemotherapeutic resection specimens of 442 breast cancer patients who had residual disease after PST were included in this study. The association between changes of biomarker status after PST and clinicopathologic features of tumors, and survival of the patients, were analyzed. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status changed after PST in 18 (4.1%), 80 (18.1%), and 15 (3.4%) patients,respectively. ER and PR mainly underwent positive to negative conversion,whereas HER2 status underwent negative to positive conversion. Negative conversion of ER and PR status after PST was associated with reduced disease-free survival. Moreover, a decline in the Allred score for PR in post-PST specimens was significantly associated with poor clinical outcome of the patients. HER2 change did not have prognostic significance. In multivariate analyses, negative PR status after PST was found to be an independent adverse prognostic factor in the whole patient group, in the adjuvant endocrine therapy-treated subgroup, and also in pre-PST PR positive subgroup. ER and HER2 status changed little after PST, whereas PR status changed significantly. In particular, negative conversion of PR status was revealed as a poor prognostic indicator, suggesting that re-evaluation of basic biomarkers is mandatory in breast cancer after PST for proper management and prognostication of patients.Keywords
Funding Information
- National Research Foundation of Korea (2015R1A2A2A01007907)
- Ministry of Science, ICT and Future Planning
This publication has 29 references indexed in Scilit:
- Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical OutcomeCancer Research and Treatment, 2016
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientistsAnnals of Oncology, 2015
- Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational studyOncotarget, 2015
- Neoadjuvant treatment of breast cancerAnnals of Oncology, 2012
- Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor–positive Breast CancerAnnals of Surgical Oncology, 2012
- The Hormonal Receptor Status in Breast Cancer can be Altered by Neoadjuvant Chemotherapy: A Meta-AnalysisCancer Investigation, 2011
- Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancerBritish Journal of Cancer, 2009
- The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancerThe American Journal of Surgery, 2003
- Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot studyBreast Cancer Research and Treatment, 1999